This is a phase I, single center, randomized, double-blind and parallel group clinical trial.~The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of MW031 and Prolia® in healthy volunteers.~The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of MW031 and Prolia® in healthy volunteers.~At the same time, preliminary evaluate the pharmacodynamic similarity between MW031 and Prolia®.~Subjects would receive a single 60mg（1mL）of MW031 or Prolia® through subcutaneous injection.
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW031 and Prolia® in healthy adults.